D. Boumpas

EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2007)

Jacobs, J Wg, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, ...

OBJECTIVE: To develop evidence based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases. METHODS: The multidisciplinary guideline development group from...

Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects

Takada, K, Danning, C, Kuroiwa, T, Schlimgen, R, Tassiulas, I, Davis, J, ...

Methods: 15 patients with active PsA who did not respond to DMARDs were randomly allocated to receive fludarabine every four weeks or placebo. Primary outcomes were the proportion of patients who met...

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit

Sidiropoulos, P, Bertsias, G, Kritikos, H, Kouroumali, H, Voudouris, K, Boumpas, D

Background: Randomised controlled trials have shown that treatment with anti-tumour necrosis factor (anti-TNF) agents is effective in refractory rheumatoid arthritis (RA).